You are here
Salarius Pharmaceuticals to Present at the 2019 World Orphan Drug Congress
HOUSTON, April 11, 2019 /PRNewswire/ -- Salarius Pharmaceuticals, LLC, a clinical-stage oncology company targeting epigenetic causes of cancers, announced that Daniela Y. Santiesteban, Ph.D., Business Development Manager, will present at the World Orphan Drug Congress USA 2019 being held April 10-12, 2019 in Oxon Hill, Maryland.
Details of Salarius' presentation are as follows:
World Orphan Drug Congress USA 2019
Seclidemstat: A reversible LSD-1 inhibitor for treatment of Ewing's sarcoma
April 12, 2019
12:35 p.m. (Eastern Time)
Gaylord National Harbor Hill, Oxon Hill, Maryland
Seclidemstat (also known as SP-2577) is an investigational agent currently being evaluated in clinical trials. It is a small molecule in development by Salarius Pharmaceuticals which inhibits lysine-specific demethylase 1 (LSD1 or KDM1A), an enzyme regulating gene expression. LSD1 has been implicated in various types of cancer, with higher levels of LSD1 associated with poor patient prognosis. Seclidemstat has been shown to inhibit LSD1's demethylation and scaffolding properties and has demonstrated potent therapeutic activity in preclinical models of Ewing sarcoma, a rare pediatric/adolescent bone cancer. In 2H2018 Salarius started a Phase 1 trial of Seclidemstat in relapsed/refractory Ewing sarcoma and plans to complete the dose escalation portion around the end of 2019.
Salarius Pharmaceuticals is a clinical-stage oncology company targeting the epigenetic causes of cancers and is developing treatments for patients that need them the most. The company's lead candidate, Seclidemstat, is currently in clinical development for treating Ewing sarcoma, for which it has Orphan Drug designation and Rare Pediatric Disease designation by the U.S. Food and Drug Administration. Salarius believes that Seclidemstat could have potential for improved safety and efficacy compared to other LSD1-targeted therapies in clinical development. Salarius is also developing Seclidemstat for a number of cancers with high unmet need and expects to commence additional clinical studies targeting advanced solid tumors, including prostate, breast and ovarian cancers. In January 2019, Salarius announced a proposed merger with publicly traded Flex Pharma, Inc., which is expected to close in the first half of 2019, subject to customary conditions. Upon closing, Salarius' clinical pipeline will become the lead assets of the combined company.
This news release includes forward-looking statements within the meaning of the U.S. federal and Canadian securities laws. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company's management. All statements, other than statements of historical facts, included in this press release regarding the Company's plans and objectives, expectations and assumptions of management are forward-looking statements. The use of certain words, including the words "estimate," "project," "intend," "expect," "believe," "anticipate," "will," "plan," "could," "may" and similar expressions are intended to identify forward-looking statements. The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the Company's forward-looking statements. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements including receipt of regulatory approvals and market conditions. The forward-looking statements are made as of this date and the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Dave Schemelia (Media)
SOURCE Salarius Pharmaceuticals, LLC